AARON KATZENMEYER: Open Payments
NPI 1538454236 · MADISON, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,000 in 107 payments from 25 companies in 2025. Trend: 2023 $1,585 · 2024 $1,739 · 2025 $2,000
Food & beverage: $2,000
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 21 | $234 |
| Axsome Therapeutics, Inc. | 7 | $232 |
| AstraZeneca Pharmaceuticals LP | 8 | $179 |
| PFIZER INC. | 10 | $174 |
| Astellas Pharma US Inc | 7 | $163 |
| Novo Nordisk Inc | 10 | $140 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $119 |
| SI-BONE, INC. | 1 | $95 |
| Otsuka America Pharmaceutical, Inc. | 5 | $89 |
| Amgen Inc. | 5 | $81 |
Products named: Veozah, UBRELVY, AIRSUPRA, Symbravo, NURTEC ODT, TRINTELLIX, Ozempic, Auvelity.
Industry payments across MS — which companies pay providers there.
